Latest Observability News

Olympio Metals has uncovered visible gold in the first hole of its maiden drilling program at the Paquin prospect within Quebec’s prolific Bousquet Gold Project, signaling promising potential ahead of assay results due mid-July.

Warriedar Resources has successfully closed an oversubscribed Share Purchase Plan, raising $9.1 million; well above its initial $2 million target; and securing a total of $21 million in funding to accelerate exploration at its Golden Range Gold Project.

Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.

Koonenberry Gold has reported strong assay results from its sixth drillhole at the Enmore Gold Project, confirming extended and continuous gold mineralisation. The company plans a fully funded follow-up drilling program to further expand this emerging discovery in NSW.

Nelson Resources reports promising initial rock chip assays from its Yarri Project in Western Australia, revealing high-grade gold exceeding 8 g/t and identifying new geological targets beyond known mineralisation zones.

Westgold Resources has unveiled a maiden Mineral Resource Estimate of 2.3 million ounces of gold at its Fletcher Zone, effectively doubling the Beta Hunt mine’s resource base and setting the stage for expanded production.

Shift4 Payments, LLC has entered into a definitive scheme implementation agreement to acquire Smartpay Holdings Limited at NZ$1.20 per share, subject to regulatory and shareholder approvals. The transaction outlines a detailed timetable and conditions, including Overseas Investment Office consent and court sanction.

Waterco Limited has disclosed a historical breach of ASX Listing Rule 10.1 involving lease agreements with a related party, prompting plans to seek retrospective shareholder approval at its 2025 AGM.

Kingsrose Mining announces the immediate resignation of Managing Director Fabian Baker and appoints industry veteran Terry Holohan as Acting CEO to steer its Scandinavian projects and acquisition strategy.

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.

Pivotal Metals has clarified the cause behind its recent share price surge, attributing it to a publicly released research note while confirming no undisclosed material information.